Evidence map›Paper›PMID 32381580›Full record

ArticleHaematologica2021

Heterogenous mutation spectrum and deregulated cellular pathways in aberrant plasma cells underline molecular pathology of light-chain amyloidosis.

Zuzana Chyra, Tereza Sevcikova, Petr Vojta, Janka Puterova, Lucie Brozova, Katerina Growkova, Jana Filipova, Martina Zatopkova, Sebastian Grosicki, Agnieszka Barchnicka and 24 more

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Haematologica, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

34 authors.

Zuzana ChyraDana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Tereza SevcikovaDpt. of Clinical studies, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic.
Petr VojtaInstitute of Molecular and Translational Medicine, Palacky University, Olomouc, Czech Republic.
Janka PuterovaBrno University of Technology, Centre of Excellence IT4Innovations, Brno, Czech Republic.
Lucie BrozovaInstitute of Biostatistics and Analyses, Masaryk University, Brno, Czech Republic.
Katerina GrowkovaDpt. of Clinical studies, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic.
Jana FilipovaDepartment of Biology and Ecology, Faculty of Science, University of Ostrava, Czech Republic.
Martina ZatopkovaDpt. of Clinical studies, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic.
Sebastian GrosickiDept. of Hematology and Cancer Prevention, Medical University of Silesia in Katowice, Poland.
Agnieszka BarchnickaDept. of Hematology and Cancer Prevention, Medical University of Silesia in Katowice, Poland.
Wieslaw Wiktor JedrzejczakDepartment of Haematology, Oncology and Internal Diseases, Medical University of Warsaw, Poland.
Anna Waszczuk-GajdaDepartment of Haematology, Oncology and Internal Diseases, Medical University of Warsaw, Poland.
Alexandra JungovaCharles University Hospital Pilsen, Czech Republic.
Aneta MikulasovaBiosciences Institute, Newcastle University, Newcastle upon Tyne, United Kingdom.
Marian HajduchInstitute of Molecular and Translational Medicine, Palacky University, Olomouc, Czech Republic.
Martin MokrejsIT4Innovations, VSB, Technical University of Ostrava, Ostrava, Czech Republic.
Ludek PourDepartment of Internal Medicine, Hematology and Oncology, University Hospital Brno, Czech Republic.
Martin StorkDepartment of Internal Medicine, Hematology and Oncology, University Hospital Brno, Czech Republic.
Lubica HarvanovaDepartment of Haematology and Transfusiology, University Hospital Bratislava, Slovakia.
Martin MistrikDepartment of Haematology and Transfusiology, University Hospital Bratislava, Slovakia.
Gabor MikalaDept. of Haematology and Stem Cell Transplantation, South Pest Central Hospital, Budapest, Hungary.
Pawel RobakDepartment of Haematology, Medical University of Lodz, Copernicus Memorial Hospital, Łódź, Poland.
Anna CzyzDept. and Clinic of Haematology, Blood Neoplasms, Wroclaw Medical University, Poland.
Jakub DebskiDept. and Clinic of Haematology, Blood Neoplasms, Wroclaw Medical University, Poland.
Lidia Usnarska-ZubkiewiczDept. and Clinic of Haematology, Blood Neoplasms, Wroclaw Medical University, Poland.
Artur JurczyszynJagiellonian University Medical College, Cracow, Poland.
Lukas StejskalSilesian Hospital Opava, Opava, Czech Republic.
Gareth MorganDpt. of Medicine, Multiple Myeloma Research Perlmutter Cancer Center, NYU School of Medicine, USA.
Fedor KryukovDepartment of Haematooncology, University Hospital Ostrava, Ostrava, Czech Republic.
Eva BudinskaRECETOX, Faculty of Science, Masaryk university in Brno, Brno, Czech Republic.
Michal SimicekDpt. of Clinical studies, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic.
Tomas JelinekDepartment of Haematooncology, University Hospital Ostrava, Ostrava, Czech Republic.
Matous HrdinkaDpt. of Clinical studies, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic.
Roman HajekDepartment of Haematooncology, University Hospital Ostrava, Ostrava, Czech Republic.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AmyloidosisImmunoglobulin Light-chain AmyloidosisHumansImmunoglobulin Light ChainsMutationPathology, MolecularPlasma CellsImmunoglobulin Light Chains

Identifiers

PMID32381580
PMCPMC7849586

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.